Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

Expert Rev Neurother. 2012 Oct;12(10):1173-6. doi: 10.1586/ern.12.107.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / administration & dosage
  • Antigens, Neoplasm / metabolism
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / immunology
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / therapy*
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Combined Modality Therapy
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Evidence-Based Medicine
  • Glioblastoma / diagnosis
  • Glioblastoma / immunology
  • Glioblastoma / metabolism
  • Glioblastoma / therapy*
  • Humans
  • Immunotherapy, Adoptive* / trends
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / metabolism
  • Prognosis

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Peptide Fragments